MarketVue®: Palmoplantar Pustulosis (PPP)
The MarketVue®: Palmoplantar Pustulosis market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
Topics covered in this report:
• Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing
Methodology:
Research for the MarketVue®: Palmoplantar Pustulosis report is supported by 6 qualitative interviews with key opinion leaders, a quantitative survey with 27 U.S. physicians and secondary research.
Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)
Key companies mentioned:
• AnaptysBio
• Boehringer Ingelheim
• Novartis
• Aristea Therapeutics
• Janssen
• Kyowa Kirin
• AbbVie
• Amgen
• CSL Behring
• Inmagene
• National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
• KHK
• Regeneron
• Eli Lilly
• Maruho
Key drugs mentioned:
• Acitretin
• Methotrexate
• Cyclosporine
• Etanercept (Enbrel)
• Adalimumab (Humira)
• Ixekizumab (Taltz)
• Brodalumab (Siliq, Kyntheum, Lumicef)
• Apremilast (Otezla)
• Ustekinumab (Stelara)
• Guselkumab (Tremfya)
• Risankizumab (Skyrizi)
• Imsidolimab
• Spesolimab (Spevigo)
• Secukinumab (Cosentyx)
• RIST4721
• CSL324
• Anumigilimab
• IMG-008
• REGN 6490
• Anakinra
• LY3041658
• Maxacalcitol
Please note: the online download version of this report is for a global site license.
- 1. DISEASE OVERVIEW
- A recurrent inflammatory disorder causing pustules on the hands and feet
- Figure 1.1 – Conditions related to PPP
- Disease pathogenesis
- Figure 1.2. Autoimmune and autoinflammatory drivers of PPP disease pathogenesis
- Figure 1.3 – Treatments effective in psoriasis are not effective in PPP
- PPP is a distinguishable disease
- Figure 1.4. Clinical and genetic differences between pustular psoriasis subtypes
- 2. EPIDEMIOLOGY & PATIENT POPULATIONS
- Disease definition
- Figure 2.1 – G6 prevalent cases of PPP by region
- Table 2.1 – Prevalent and drug-treated populations of PPP in the U.S. and EU5
- 3. CURRENT TREATMENT
- Overview
- Figure 3.1 – Treatment goals for PPP
- Standard of care
- Figure 3.2 – Current treatment patient share
- TNF inhibitors and IL-17 inhibitors are the most commonly used biologics in PPP
- Figure 3.3 – Dermatologist-reported biologic use in PPP patients by drug class
- Figure 3.4. Percentage of PPP patients who proceed from first-line to a second-line biologic
- Figure 3.5 – Dermatologist preferred second-line biologic
- Dermatologists choose biologics that are effective in psoriasis
- Treatment decisions for PPP
- Figure 3.6 – Treatment algorithm for PPP
- Dermatologists tend to categorize PPP as a form of psoriasis
- Figure 3.7 – Dermatologists’ opinion on the relationship between PPP and psoriasis
- Figure 3.8. Evolution of PPP as a distinct indication
- Current PPP treatment options are minimally effective
- Table 3.1 – Upside and downsides of currently off-label PPP treatments
- Current treatment options have their limitations
- Key treatment dynamics that shape disease management and drug use
- Table 3.2 – Must-know PPP treatment dynamics for now and the future
- Figure 3.9 – Percentage of PPP patients who are not achieving satisfactory outcomes with current treatments
- PPP has a severe psychosocial and quality of life impact on patients
- Figure 3.10 – Dermatologists’ rating of the impact of PPP on patients
- First approved therapies for PPP likely to be label expansions
- Figure 3.11 – Important dynamics of PPP market evolution
- 4. UNMET NEED
- Overview
- Top unmet needs in PPP
- Figure 4.1 – Dermatologist-reported unmet needs in PPP
- Physician perspectives on unmet needs in PPP
- Figure 4.2 – U.S. dermatologists ranking of the need for new treatments in dermatology
- 5. PIPELINE ANALYSIS
- Drug development for PPP
- Figure 5.1 – Number of clinical stage therapies addressing unmet needs in PPP
- Figure 5.2 – Percent of U.S. dermatologists rating PPP emerging therapy target as “promising”
- Opinions are mixed on which MOA is the most promising
- Summary of clinical-stage emerging PPP therapies
- Table 5.1 – Emerging PPP therapies, Phase 1 to Phase 3
- Competitor pipeline overview
- Figure 5.3. – Current pipeline shows several therapies in varying stages of development
- 6. VALUE & ACCESS
- Overview
- Table 6.1 – Current therapy pricing, US 2021
- Biologics require prior authorization on commercial insurance plans
- Figure 6.1 – Reimbursement and Access considerations for emerging therapies in PPP
- Medicare reimbursement stands to be a high barrier for patient access to novel PPP therapies
- Regulatory considerations in PPP
- Figure 6.2. – Key regulatory factors in PPP
- 7. METHODOLOGY
- Primary market research approach
- Epidemiology methodology
- Disease overview
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook